New system for detecting drug side effects can beat regulatory agency

selenium can reduce the side effects of cisplatin as a chemotherapy drug

New regulatory framework for cancer drug development.

Recent changes to non-clinical cancer guidelines offer a golden opportunity to expedite the translation of new anticancer drugs into the clinic. In this review we look at how these guidelines can be implemented and how they can be integrated with non-clinical and clinical study design to produce robust and safe clinical trials.

A new self-rating scale for detecting atypical or second-generation antipsychotic side effects.

We aimed to construct and assess a new self rating scale to detect the side effects of second generation antipsychotics. This scale was designed to allow a timely, sensitive and reliable method of gathering information on the number and severity of side effects an individual suffers from. The Glasgow Antipscyhotic Side-effect Scale (GASS) was developed after literature review, discussion with m...

Can we beat influenza?

or the past 65 years, the Global Influenza Surveillance and Response System (GISRS), coordinated by the World Health Organization (WHO), has engaged in open and efficient sharing of information, viruses, and responsibilities. The GISRS’s extraordinary longevity can be attributed to several generations of dedicated scientists and to the engagement of over 100 countries, often with limited resour...

Sugammadex: watch out for new side effects

US Food and Drug Administration (FDA) approved sugammadex for the reversal of neuromus-cular blockade induced by rocuronium bromide or vecuronium bromide in adults who received either of these neuromuscular blocking agents during surgery. After its approval in Europe in 2008, sugammadex has been approved in more than 70 countries. However, the US FDA has been postponing its approval, citing con...